Answers are grounded in this paper and cite their sources.
Immunotherapy has emerged as a promising approach for osteosarcoma, but its clinical translation is hampered by the complexity of current therapeutic systems. Here, we developed a simple nanodrug composed of Cu 2+ and liensinine (Lis) that amplifies tumor cell damage by simultaneously blocking autophagic flux and inducing cuproptosis. Mechanistically, Cu 2+ depletes glutathione and disrupts intracellular redox homeostasis, thereby weakening antioxidant defenses and increasing copper‐associated mitochondrial stress. This process is accompanied by FDX1 upregulation and cuproptosis‐associated mitochondrial dysfunction. In parallel, liensinine impairs lysosomal integrity and blocks autophagosome clearance, thereby preventing the efficient removal of damaged mitochondria and allowing ROS accumulation to persist. Sustained oxidative stress then activates caspase‐3, which cleaves GSDME to generate the pore‐forming GSDME‐N fragment, resulting in plasma membrane permeabilization and subsequent release of damage‐associated molecular patterns, thereby enhancing hallmarks of immunogenic cell death and facilitating dendritic cell maturation. In vivo, Cu‐Lis suppresses osteosarcoma growth, increases intratumoral immune‐cell infiltration, and reduces pulmonary metastasis. Collectively, this work provides a streamlined strategy that integrates autophagic flux blockade with cuproptosis to potentiate antitumor immunity against osteosarcoma.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: